Drug Profile
Research programme: antibody-based immunotherapeutics - Pieris Pharmaceuticals
Alternative Names: ENUM 388D4Latest Information Update: 07 Sep 2023
Price :
$50
*
At a glance
- Originator Enumeral Biomedical Holdings
- Class Immunoconjugates; Lipocalins; Proteins
- Mechanism of Action Immunologic cytotoxicity; Programmed cell death-1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Cancer in USA (Parenteral) (before September 2023)
- 28 May 2020 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 06 Jun 2016 Pieris Pharmaceuticals expands the licensing agreement for anti-PD-1 antibody program (ENUM 388D4) from Enumeral Biomedical